The U.S. Senate passed a sweeping economic package aimed at lowering healthcare costs and combating climate change on Sunday. The Inflation Reduction Act of 2022 includes a cap on Medicare patients' ...

A bill that would cap the price of insulin in California at $35 for a 30-day supply has been approved by the state legislature and is heading to Gov. Gavin Newsom's desk. Senate Bill 40 by State Sen.

More drug companies lowered list prices for insulin this week. NPR's Scott Simon speaks with Kaiser Health News reporter Bram Sable-Smith about what that means for patients. More good news for the ...

SACRAMENTO, Calif. — California is capping the price of insulin to help the millions of Californians diagnosed with diabetes. Governor Gavin Newsom signed a new law that will limit copays for a 30-day ...

SACRAMENTO -- On Saturday Gov. Gavin Newsom announced the approval of Senate Bill 770, introduced by Sen. Scott Wiener (D-San Francisco). The legislation advances tangible steps toward securing ...

The axing of the insulin cap provision in the Senate’s budget reconciliation deal would leave millions of people scrambling to cover exorbitant out-of-pocket prices for the diabetes medication.

President Joe Biden is campaigning on his success in getting seniors with diabetes a $35-per-month cap on their insulin spending. But his Republican opponent, former President Donald Trump, claimed ...

The cost of insulin remains a barrier for many Americans with diabetes who depend on the drug, research published Monday suggests. A study in the Annals of Internal Medicine found that in 2021, nearly ...

Sanofi Set to Offer Insulin Products at $35 Per Month for All US Patients (Reuters) -French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to ...

Millions of patients rely on insulin. But with new drugs, some have been able to lower their doses or stop taking it altogether. By Dani Blum For over 20 years, Betsy Chadwell carried her insulin pens ...

Heavyweight insulin-maker Novo Nordisk said Tuesday that it will lower list prices for some of its insulin products by up to 75 percent by the end of the year, following in the footsteps of Eli Lilly, ...